Web Research
The Bottom Line from the Web
Daqo's Q1 2026 sales volume collapsed to 4,482 MT while production stayed at 43,402 MT, leaving revenue at $26.7M and gross margin at -521.5%. The stock fell 12.89% intraday to $19.12. The investment case is no longer "low-cost polysilicon producer with cash"; it is a policy-and-cycle bet on Chinese capacity discipline, below-cost pricing enforcement, and Daqo's willingness to preserve inventory instead of selling into a broken market. The $2.0B cash position (zero debt) is the entire near-term thesis, and it shrank by ~$270M in the quarter.
Q1 2026 Revenue
Q1 Gross Margin
Cash-Like Assets
Consensus Target
What Matters Most
1. Q1 2026 print: revenue down 88% QoQ, gross loss $139M, stock -12.89%
Q1 2026 (announced Apr 29, 2026): revenue $26.7M vs $221.7M in Q4 2025; gross loss $139.4M (margin -521.5%); net loss $88.4M ($1.31/ADS); EBITDA negative $83.1M. Production beat guidance at 43,402 MT, but sales volume fell to 4,482 MT vs 38,167 MT in Q4. Inventory impairment provisions and ASPs below production cost did the damage. Stock fell 12.89% intraday to $19.12. Source: Daqo Q1 2026 results.
The disconnect between production (above guidance) and sales (collapsed) is the key signal: management is betting the cycle turns and is willing to absorb impairments to stay in market position. Management said market prices moved below production cost during Q1 and that Daqo followed Chinese self-regulation guidelines by declining below-cost sales — meaning near-term revenue can stay artificially depressed if the company waits for policy-led capacity rationalization rather than clearing inventory.
2. The 2025 recovery narrative reversed quickly
FY2025 net loss narrowed to $170.5M from $345.2M in 2024; EBITDA turned positive at $1.7M; operating cash flow positive $66.1M vs negative $435M in 2024. Q3 2025 alone hit positive EBITDA of $45.8M and adjusted net income of $3.7M, with cash cost at a record-low $4.54/kg. Q1 2026 then reset the story entirely: EBITDA fell to negative $83.1M and net loss widened sequentially to $88.4M. Sources: FY2025 results and Q1 2026 results.
3. Liquidity is the main offset, but it is shrinking
Daqo reported $2.00B of cash, short-term investments, bank notes receivable, held-to-maturity investments, and fixed-term bank deposits at March 31, 2026, with zero debt. The same pool was $2.27B at Q4 2025. The cushion fell by ~$270M in one quarter. Source: Q1 2026 results.
4. Inventory and asset write-down risk is recurring
Inventory impairment provisions are a recurring driver of headline losses: cited explicitly in Xinjiang Daqo's RMB2.6-3.1B FY2024 loss disclosure, in Q1 2025 ($81.5M gross loss), in Q4 2024 ($175.6M long-lived asset impairment), and again as the primary driver of the Q1 2026 -521.5% gross margin. A $19.3M allowance for credit losses in Q4 2025 was tied to long-outstanding receivables from a "local government-affiliated industrial park development entity" in Inner Mongolia — quietly disclosing that Daqo had been bankrolling local government infrastructure during the boom. Sources: Q1 2026 results and FY2024 results.
5. Xinjiang exposure remains a structural overhang
Daqo's Xinjiang subsidiary was placed on the US Commerce Department's Entity List in June 2021 and remains there. FY2025 20-F coverage flags Xinjiang-related sanctions and forced-labor concerns. This is the structural reason the US market is closed to Daqo and the unspoken constraint behind every "overseas expansion" deferral. Sources: Daqo company history and FY2025 20-F.
6. Analyst sentiment is split between deep value and value trap
Consensus rating: Hold with target ~$25.43 (MarketBeat Apr 2026). Yahoo 1-year estimate $31.86; range $14.14-$40.95 (fintel.io). GLJ Research downgraded to Sell on Feb 3, 2026 with an $18.13 target, citing -34.2% gross margins and a 30% revenue decline. Roth Capital cut from $30 to $25 and maintained Neutral after Q4 results. Q4 2025 missed: EPS -$0.11 vs consensus -$0.04, on $221.7M revenue vs $276.9M consensus. Sources: Benzinga analyst ratings and Roth target cut.
7. Family-controlled governance with concentrated power
On Aug 3, 2023, founder Guangfu Xu stepped down as Chairman and CEO Longgen Zhang resigned "due to personal reasons" — both on the same press release. Rosen Law and Schall Law Firm announced investor investigations. On Oct 30, 2024, CEO Xiang Xu's daughter Xiaoyu Xu was promoted to Deputy CEO after a 17-month path from IR Director. Xiang Xu's March 2026 Form 3 shows 38.7M ordinary shares controlled — roughly half through two BVI entities (Duke Elite Limited, Plenty China Limited). Sources: leadership change and Xiaoyu Xu appointment.
8. Buyback authorized but on hold; no dividend
A $100M share repurchase program was authorized in July 2024 and another $100M in August 2025. FY2025 filing says no ADS or ordinary share repurchases were made under either program. Management explicitly said "wait-and-see stance" pending consolidation cash needs. DQ has never paid a dividend. Source: FY2025 results.
9. Mixed institutional flow — selling outweighs buying
In the most recent 13F cycle: FengHe Fund cut its stake 56.9% (sold 267,462 shares, leaving 202,371 shares worth ~$5.97M). Waterfront Wealth cut 33.4%. On the buying side, Ariose Capital bought 118,500 shares (Apr 25, 2026). BlackRock holds ~2.2%. Total institutional ownership: ~47.22%.
10. Related-party precedent: insiders bought into Xinjiang Daqo for STAR Market
In June 2020, Daqo sold 4.4% of Xinjiang Daqo (the principal operating subsidiary, ~72.4% owned) to four named insiders — Chairman Guangfu Xu, director Xiang Xu, director Dafeng Shi, and then-CEO Longgen Zhang — for ~RMB199M (~$28M). The transaction was structured to satisfy the STAR Market's "multiple shareholders" listing requirement.
Recent News Timeline
What the Specialists Asked
Insider Spotlight
Ownership picture: CEO ~9.35% personally (per Simply Wall St); institutions ~47% of float, dominated by passive index holders (Continental General Insurance, Vanguard, Franklin Resources, Polunin, Invesco, Morgan Stanley, Mackenzie, Arrowstreet, State Street, BlackRock at ~2.2%). Recent active flow leans bearish — FengHe Fund cut 56.9%, Waterfront Wealth cut 33.4%, partially offset by Ariose Capital adding 118,500 shares (Apr 25, 2026).
Industry Context
China's polysilicon market is undergoing an overcapacity reset. Daqo's Q1 2026 release said N-type polysilicon prices fell sharply from end-2025 levels by quarter-end, while industry-level monthly polysilicon supply fell to ~93,000 MT and average utilization was only 39%.
Policy is now part of the investment thesis. Management cited an April 17, 2026 meeting by MIIT, NDRC, the State Administration for Market Regulation (SAMR), the National Energy Administration, and other departments to regulate solar PV competition, with measures covering capacity regulation, standards, price-law enforcement, quality supervision, mergers and acquisitions, and intellectual property. SAMR had separately halted SPV consolidation proceedings on January 6, 2026 with an antitrust review, adding another variable to the timeline for industry rationalization.
The competitive edge, if it exists, is cost and staying power. Daqo had $2.00B in cash-like assets and zero debt, Q1 2026 cash cost was $4.59/kg, and management describes the company as one of the lowest-cost N-type polysilicon producers. That balance sheet lets Daqo wait, but the same strategy depresses near-term revenue when below-cost sales remain off the table. The competitive set is Chinese (GCL, Tongwei); US/global solar comparables (FSLR, JKS, CSIQ, ENPH) operate downstream and are not direct polysilicon competitors.
Bull case: capacity rationalization by higher-cost producers should restore supply-demand balance, with global polysilicon demand projected to grow 12.8% annually as solar PV deployment continues. At 0.30x book with $2B net cash and negative enterprise value, the market prices zero recovery.
Bear case: industry remains 2x oversupplied at nameplate even after retirement scenarios; SPV consolidation cost range is "RMB10-30B"; the anti-involution narrative has been "finally serious" since Q3 2024 without clearing inventory; and the $2.0B cash cushion is eroding at ~$270M per quarter under current operating conditions.